Navigating Inavolisib Treatment Safely: Adverse Events Explained
Inavolisib (Itovebi) 3 mg and 9 mg tablets for PIK3CA-mutated breast cancer treatment. Every patient is different in responding to the same treatment. For some, it may show good therapeutic effects to some; for others, it may lead to harmful events. While the positive outcomes are widely recognised, this article focuses on the most overlooked adverse events. Understanding Inavolisib’s (Itovebi) Action PIK3CA is a gene that provides instructions for making a part of an enzyme called PI3K. When a mutation occurs in the PIK3CA gene, the PI3K pathway can become overactive, which may encourage breast cancer cells to grow and survive. Inavolisib , the active ingredient in Itovebi, works by targeting the effects of the abnormal PIK3CA mutation and helping slow down the growth and spread of cancer cells. Inavolisib is used in combination with palbociclib and fulvestrant to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast...